BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

80.25 +6.92 (+9.43%)

Streaming Delayed Price Updated: 10:17 AM EST, Feb 12, 2026 Add to My Watchlist

Price and Volume

Volume	3,429,863
Open	84.84
Bid (Size)	80.10 (200)
Ask (Size)	80.39 (400)
Prev. Close	73.33
Today's Range	78.95 - 84.94
52wk Range	28.32 - 81.33
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

Today 10:20 EST

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗

Today 8:00 EST

The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism.

Via Stocktwits

Performance

YTD	+2.6%	+2.6%
1 Month	+4.4%	+4.4%
3 Month	+21.2%	+21.2%
6 Month	+59.3%	+59.3%
1 Year	+157.9%	+157.9%

More News

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

Today 7:30 EST

From BridgeBio Pharma, Inc.

Via GlobeNewswire

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Via MarketMinute

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

January 16, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

January 14, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

January 05, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Via MarketMinute

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

January 02, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 22, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Via The Motley Fool

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Via Investor's Business Daily

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

BridgeBio to Participate in December Investor Conferences

November 25, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

November 19, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

Via MarketMinute

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

November 08, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

BridgeBio to Participate in November Investor Conferences

November 04, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

November 03, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 80.25

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 02/12/26 10:17 AM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.88B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.